β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis
- PMID: 31704215
- DOI: 10.1016/j.ijantimicag.2019.10.020
β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis
Abstract
Background: Combining aminoglycosides with β-lactam antibiotics for treating serious infections has not been associated with reduced mortality in previous meta-analyses. However, the multiple daily aminoglycoside dosing regimen principally used in most of the included studies is inconsistent with current practice.
Objective: To determine if a combination of an aminoglycoside administered as a single daily dose and a β-lactam antibiotic reduces all-cause mortality in patients compared with β-lactam antibiotic monotherapy.
Methods: A systematic review and meta-analysis of clinical studies was performed (Prospero registration number #68506). Studies were included if they compared β-lactam antibiotic monotherapy with combined β-lactam and single daily dose aminoglycoside therapy for treating serious infections. Studies investigating multiple daily dosing aminoglycoside regimens, infective endocarditis and febrile neutropaenia were excluded. Study quality was assessed using the PEDro and Newcastle-Ottawa scoring systems. The end points for outcome analyses were 30-day all-cause mortality, clinical cure and nephrotoxicity.
Results: Four randomised controlled trials and five retrospective cohort studies were analysed. Compared with β-lactam antibiotic monotherapy, single daily aminoglycoside dosing in combination with β-lactam antibiotics was not associated with reduced mortality compared with β-lactam antibiotic monotherapy (n = 3686, OR 0.82, 95% CI 0.63-1.08, P = 0.10, I2 42%). A subgroup analysis of cohort studies suggested reduced mortality with combination therapy (n = 3563, OR 0.79, 95% CI 0.64-0.99, P = 0.04, I2 32%). No increased risk of nephrotoxicity was identified (n = 1110, OR 1.31, 95% CI 0.83-2.09, P = 0.40, I2 0%).
Conclusions: The existing evidence suggests no added survival benefit from a single daily dosing regimen of an aminoglycoside when combined with β-lactam antibiotics.
Keywords: Aminoglycoside; Beta-lactams; Combination; Sepsis; Septic shock.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Similar articles
-
Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.Clin Infect Dis. 2005 Jul 15;41(2):149-58. doi: 10.1086/430912. Epub 2005 May 31. Clin Infect Dis. 2005. PMID: 15983909
-
Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials.Mayo Clin Proc. 2005 Sep;80(9):1146-56. doi: 10.4065/80.9.1146. Mayo Clin Proc. 2005. PMID: 16178494
-
The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.J Antimicrob Chemother. 2006 Apr;57(4):639-47. doi: 10.1093/jac/dkl044. Epub 2006 Feb 24. J Antimicrob Chemother. 2006. PMID: 16501057 Review.
-
β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.Int J Antimicrob Agents. 2013 Apr;41(4):301-10. doi: 10.1016/j.ijantimicag.2012.12.006. Epub 2013 Feb 12. Int J Antimicrob Agents. 2013. PMID: 23410791 Review.
-
Extended-interval aminoglycoside administration for children: a meta-analysis.Pediatrics. 2004 Jul;114(1):e111-8. doi: 10.1542/peds.114.1.e111. Pediatrics. 2004. PMID: 15231982
Cited by
-
Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.Respirology. 2023 Apr;28(4):339-349. doi: 10.1111/resp.14479. Epub 2023 Mar 2. Respirology. 2023. PMID: 36863703 Free PMC article.
-
Leveraging laboratory and clinical studies to design effective antibiotic combination therapy.Curr Opin Microbiol. 2021 Dec;64:68-75. doi: 10.1016/j.mib.2021.09.006. Epub 2021 Oct 8. Curr Opin Microbiol. 2021. PMID: 34628295 Free PMC article. Review.
-
Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials.BMC Med. 2021 Dec 6;19(1):307. doi: 10.1186/s12916-021-02176-1. BMC Med. 2021. PMID: 34865623 Free PMC article. Review.
-
Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.Int J Antimicrob Agents. 2023 Oct;62(4):106913. doi: 10.1016/j.ijantimicag.2023.106913. Epub 2023 Jul 6. Int J Antimicrob Agents. 2023. PMID: 37422096 Free PMC article.
-
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451. J Antimicrob Chemother. 2025. PMID: 39691958 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical